The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Alliance digital tool proves effective at keeping patients engaged in trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A pilot project reveals that 84% of participants had a positive experience using a newly developed online tool created by the Alliance for Clinical Trials in Oncology called the Participant Engagement Portal. Alliance created PEP to foster direct connection between cancer researchers and the individuals who volunteer for clinical studies. The goal was to make it easier for patients and clinicians to share information, deliver trial updates, and self-report on social risk factors. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

Community sites have the patients to boost trial enrollment—but not the infrastructure

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.
By Gordon Harris
Clinical Roundup

Tarlatamab + durvalumab extends survival for patients with aggressive small cell lung cancer, phase III trial finds

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to the results of the phase III open-label, multicenter, randomized DeLLphi-305 study. 
Clinical Roundup

Tarlatamab + durvalumab extend median OS for patients with ES-SCLC, phase III DeLLphi-305 trial finds

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase III open-label, multicenter, randomized DeLLphi-305 study.
Clinical Roundup

Divarasib monotherapy improves OS in previously-treated KRAS G12C-mutated lung cancer, phase III trial finds

Divarasib, a next-generation KRAS G12C inhibitor, lowered the risk of disease progression or death by 42% and the overall risk of death by 44% in people with previously treated KRAS G12C-mutated non-small cell lung cancer, according to the results from the phase III Krascendo 1 study. The therapy demonstrated the superior efficacy compared with current standard of care KRAS G12C inhibitors. 
Clinical Roundup

Perioperative Imfinzi + Padcev improves EFS, OS, in MIBC, phase III trial finds

Perioperative Imfinzi (durvalumab) plus neoadjuvant Padcev (enfortumab vedotin) reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer, according to the VOLGA phase III trial. The combination demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival and key secondary endpoint of overall survival in patients with muscle-invasive bladder cancer versus standard of care. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account